Treatment of Degenerative Disc Disease With Allogeneic Mesenchymal Stem Cells: Long-term Follow-up Results

间充质干细胞 医学 干细胞 随机对照试验 纳入和排除标准 变性(医学) 退行性椎间盘病 骨髓 间质细胞 生活质量(医疗保健) 临床试验 疾病 移植 外科 病理 内科学 生物 替代医学 腰椎 护理部 遗传学
作者
David C. Noriega,Francisco Ardura,Rubén Hernández-Ramajo,Miguel Ángel Martín-Ferrero,I. Sánchez Lite,Borja Toribio,Mercedes Alberca,Verónica García,José M. Moraleda,Margarita González‐Vallinas,Ana Sánchez,Javier García‐Sancho
出处
期刊:Transplantation [Ovid Technologies (Wolters Kluwer)]
卷期号:105 (2): e25-e27 被引量:15
标识
DOI:10.1097/tp.0000000000003471
摘要

Degenerative disc disease frequently results in severe low back pain, which represents a public health problem with great economic and quality of life impact. Chronic cases often require surgery, which can lead to biomechanical problems and accelerated degeneration of the adjacent segments.1,2 Both autologous3 and allogeneic4 mesenchymal stromal cell (MSC) treatments have shown feasibility, safety, and strong indications of clinical efficacy 1 year after cell transplantation. Allogeneic cells are logistically more convenient for generalized treatment (see discussion in Noriega et al4), and the durability of the effect is essential. We present here the long-term (3.5 ± 0.1 y; mean ± SEM; n = 23) results of our randomized, controlled trial using allogeneic bone marrow-derived MSCs.4 We originally randomized 24 patients, 17 men and 7 women, with chronic back pain diagnosed with lumbar disk degeneration (to 1 or 2 discs) and unresponsive to conservative treatments into 2 groups. The mean (±SEM) age was 38 years (±2 y). The further details of the baseline demographics and the inclusion and exclusion criteria are given in Noriega et al.4 The bone marrow cells were obtained from healthy donors, purified, and expanded for 24–27 days (3 passages) under Good Manufacturing Practice criteria (details in Orozco et al3 and Noriega et al4). The treatment group received the allogeneic bone marrow MSCs as intradisc injections of 25 × 106 cells per segment under local anesthesia. The control group received sham infiltration in the paravertebral musculature with the anesthetic. Clinical outcomes were followed for 1 year, and included evaluation of pain (Visual Analog Scale: 0–100), and disability (Oswestry Disability Index).5 Disc quality was followed using MRI and quantified according to the Pfirrmann grading (1–5). Feasibility and safety were confirmed, and indications of clinical efficacy were identified. The MSC-treated patients showed rapid and significant improvements in the algofunctional indices versus the controls. Furthermore, disc degeneration quantified by the Pfirrmann grading improved in the MSC-treated patients and worsened in the controls.4 Here, we report the results of the patient follow-up at (mean ± SE; n = 23) 3.5 ± 0.1 years from the original interventions. No serious adverse effects were recorded during this extension period for either treatment or control group. Figure 1A–D summarizes the evolution of the clinical data. For the test group, the early pain improvements and the Oswestry Disability Index improvements during the first year persisted 3.5 years later (Figure 1A and B). The therapeutic efficiency of the MSC treatment was estimated from the pain relief and the disability improvement in the Huskisson plot and was 0.28 at 1 year after the intervention. By 3.5 years, the therapeutic efficiencies increased to 0.60 (pain relief) and 0.71 (disability) (Figure 1C and D). The control patients did not show any significant healing at 3.5 years after intervention (efficiency, 0.18 for pain, 0.0 for disability; Figure 1C and D, respectively). Of note, the MSC-treated patients showed 2 distribution patterns: one as a subpopulation of “responders” who lie close to the “perfect treatment” line and the other as a subpopulation of “non responders” with no significant difference from the control patients (Figure 1C and D).FIGURE 1.: Pain, disability, and Pfirrmann grading evolution for the control and mesenchymal stromal cell (MSC)-treated patients. A, Evolution over time of lower back pain measured by a Visual Analog Scale (VAS; expressed as 0%–100%). Data are means ± SD for the control group (inverted triangles) and the MSC-treated group (filled circles). B, Evolution over time of disability measured by the Oswestry Disability Index (ODI) (expressed as 0%–100%).5 Other details as in (A). C and D, Correlations between improved lower back pain (C, VAS) and disability (D, ODI) and the initial baseline values for each patient,6 measured at 42 mo from the intervention (3.5 ± 0.1 y; n = 23). The discontinuous blue line shows the slope of 1.0 that represents “perfect treatment” with complete relief of pain (C) and disability (D). The slopes of the lines are given at the right. Other details as in (A). E and F, MRI assessment of nucleus pulposus evolution according to the Pfirrmann grading. The Pfirrmann grading measures affectation (grades 1–5), taking into account the structure of the disc, the distinction of the nucleus pulposus and the annulus fibrous, the signal intensity, and the height of the disc. Data are means ± SE for baseline (0) and 6, 12, and 42 mo (ie, 3.5 y) after the intervention for the control group (E) and the MSC-treated group (F). *P < 0.05; **P < 0.01; ***P < 0.001 vs baseline (ANOVA, Bonferroni multiple comparisons). NS, not significant.For the structural changes of the affected discs, at the end of the first year of treatment, we reported significant improvements for the MSC treatment, as seen by the decreased Pfirrmann gradings defined from MRI.4 At 3.5 years, the decreased Pfirrmann grading was maintained in the MSC-treated patients (P < 0.01 versus baseline), whereas the control patients showed indication of continued increase in the Pfirrmann grading (P < 0.001 versus baseline). Thus, from baseline to 42 months, the Pfirrmann grading significantly increased in the controls by 1.0 (baseline, 3.15; 42 mo, 4.16; Figure 1E), whereas for the MSC-treated patients, there was a significant decrease of >0.6 (baseline, 3.59; 42 mo, 2.94; Figure 1F). This contrasts with the repeatedly reported rapid clearance of MSCs from living tissues.7 This persistent improvement of the phenotype achieved has been attributed to epigenetic actions of the MSCs.8,9 Overall, these long-term data reaffirm that MSCs appear to be a valid alternative for treatment of degenerative disc disease because they can provide effective and durable pain relief together with objective improvements to disc degeneration. This intervention is also simple, although the MSC production process is expensive. The major limitations are the difficulties to generalize the results to large populations, as well as the lack of detailed determination of the optimal dosage of cells. New studies are under way to confirm the durable results reported here in a large series of patients (eg, the pan-European RESPINE clinical trial), and to investigate upgrades to the MSC production protocol, to make the generalization of this MSC therapy possible. ACKNOWLEDGMENTS We thank Mr. Jesús Fernández from IBGM, Ms. Sandra Güemes from Citospin, and Ms. Carmen Barbero from ITRT for their technical support.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
科研通AI2S应助五十不同采纳,获得10
2秒前
爆米花应助五十不同采纳,获得10
2秒前
脑洞疼应助五十不同采纳,获得30
2秒前
知性的梨愁完成签到,获得积分10
3秒前
CipherSage应助杨涵采纳,获得10
3秒前
真实的芹关注了科研通微信公众号
3秒前
大个应助科研通管家采纳,获得10
4秒前
Owen应助科研通管家采纳,获得10
4秒前
Jeffery426发布了新的文献求助10
4秒前
4秒前
4秒前
5秒前
Weiming完成签到,获得积分10
5秒前
无花果应助Yuxzzr采纳,获得10
7秒前
小蘑菇应助Hany采纳,获得10
9秒前
cc完成签到,获得积分10
9秒前
10秒前
洗衣液发布了新的文献求助10
10秒前
典雅怀薇完成签到,获得积分10
11秒前
Shane完成签到,获得积分10
11秒前
11秒前
情怀应助奋斗不止采纳,获得10
12秒前
NexusExplorer应助俊逸的冰薇采纳,获得10
13秒前
李健应助HTB采纳,获得10
13秒前
Jasper应助小橙采纳,获得10
14秒前
开放的白晴应助研究生采纳,获得10
14秒前
Elvin2527完成签到,获得积分10
15秒前
LDDD发布了新的文献求助10
15秒前
Owen应助淡然的曼岚采纳,获得10
15秒前
qw发布了新的文献求助10
17秒前
大彬子完成签到,获得积分10
17秒前
迟大猫应助502s采纳,获得10
18秒前
orixero应助深情映冬采纳,获得10
19秒前
光亮的寻雪完成签到 ,获得积分10
21秒前
wei完成签到,获得积分10
21秒前
22秒前
23秒前
24秒前
行路1发布了新的文献求助10
26秒前
27秒前
高分求助中
Production Logging: Theoretical and Interpretive Elements 2700
Mechanistic Modeling of Gas-Liquid Two-Phase Flow in Pipes 2500
Kelsen’s Legacy: Legal Normativity, International Law and Democracy 1000
Handbook on Inequality and Social Capital 800
Conference Record, IAS Annual Meeting 1977 610
Interest Rate Modeling. Volume 3: Products and Risk Management 600
Interest Rate Modeling. Volume 2: Term Structure Models 600
热门求助领域 (近24小时)
化学 材料科学 生物 医学 工程类 有机化学 生物化学 物理 纳米技术 计算机科学 内科学 化学工程 复合材料 基因 遗传学 物理化学 催化作用 量子力学 光电子学 冶金
热门帖子
关注 科研通微信公众号,转发送积分 3546676
求助须知:如何正确求助?哪些是违规求助? 3123726
关于积分的说明 9356475
捐赠科研通 2822353
什么是DOI,文献DOI怎么找? 1551369
邀请新用户注册赠送积分活动 723332
科研通“疑难数据库(出版商)”最低求助积分说明 713721